Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: DermTech, Devyser, Prenetics, Proteomics International, Genetic Technologies

NEW YORK – Proteomics International said this week that it has appointed medical device sales firm Growth Medics to help recruit and manage new partners and customers for the PromarkerD diabetic kidney disease test in Europe. Growth Medics will aid Proteomics International with business development, marketing, and administrative support from its Netherlands office, including attending trade shows, customer service, and training. Initially, it will target new licensing and sales opportunities in the Netherlands, Belgium, Italy, and Spain, Perth, Australia-based Proteomics International said. PromarkerD is a prognostic test for predicting kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease. 

Australian genetics testing firm Genetic Technologies said this week that it has started testing operations in the US for its GeneType genetic risk assessment products. Houston-based specialty genetic lab Gene by Gene will perform the testing. The lab can process as many as 25,000 tests each month, Genetic Technologies said, adding that a previously announced distribution deal with Stay Healthy puts GeneType in a position for "exponential growth" in the US. The GeneType Multi-Risk Test uses buccal swab samples and clinical risk factors to generate scores for a patient's risk of breast, colorectal, ovarian, pancreatic, and prostate cancers, melanoma, atrial fibrillation, coronary artery disease, and type 2 diabetes. 

Devyser said this week that it expanded its distribution and commercialization agreement with Thermo Fisher Scientific. The agreement now grants Thermo Fisher exclusive rights to commercialize Devyser’s post-transplant next-generation sequencing test portfolio, which includes the One Lambda Devyser Chimerism and One Lambda Devyser Accept assays, globally. Previously, Thermo Fisher had exclusive commercialization rights in North America, Europe, Brazil, and Saudi Arabia. 

Prenetics this week announced its Q1 2024 financial results, reporting that its revenues increased 30 percent to $6.4 million from $4.9 million in the prior-year quarter. The company saw a net loss of $9.1 million, or $.70 per share, compared to a loss of $11.0 million, or $.99 per share, in Q1 2023. The firm ended the quarter with $86.6 million in cash and other short-term investments. Prenetics reaffirmed that it expects 2024 revenues to be between $33 million and $36 million. 

DermTech this week received notice from the Nasdaq that its stock will be delisted from the stock exchange as a result of its Chapter 11 bankruptcy filing, according to a document filed with the US Securities and Exchange Commission. Trading of the firm's stock will be suspended on June 27. DermTech does not plan to appeal the decision. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.